Source: Pharamceutical Technology

Tetra: Tetra receives rare paediatric disease designation for FXS therapy

Tetra Therapeutics has received rare paediatric disease designation from the US FDA for zatolmilast to treat Fragile X syndrome (FXS).

Read full article »

Tetra's Competitors | Tetra's News | Tetra's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

25-100

CEO

Chad A. Coberly

CEO Approval Rating

90/100

Tetra Discovery is a Michigan-based biotechnology firm that develops compounds for the treatment of brain disorders associated with cognitive and memory deficits.